As anti‐VEGF therapy (e.g. bevacizumab) has been applied in the management of ovarian and cervical cancer, we advocate for research on whether NF‐κB pathway inhibitors could synergise with anti‐VEGF treatment to improve therapeutic efficacy. This evidence concerns the gene VEGFA and cervical cancer.